Clinomic has secured a €23 million Series B investment led by DeepTech & Climate Fonds to expand its AI-driven healthcare solutions for critical care.
Target Information
Clinomic is a pioneering medical technology startup founded in 2019 by intensive care physicians from RWTH Aachen University Hospital. The company is focused on transforming intensive care medicine through its innovative platform, Mona, which integrates artificial intelligence and data analytics to streamline workflows within intensive care units (ICUs). Mona is designed to record, organize, analyze, and visualize patient and operational data, thereby providing healthcare professionals with real-time insights to enhance decision-making and improve overall clinical outcomes.
With a focus on addressing the unique challenges faced in high-acuity medical settings, Clinomic aims to optimize workflows and reduce administrative burdens. By utilizing AI-driven solutions, the company seeks to maximize the efficiency of ICU operations and enhance patient care, making it a leader in the critical care technology sector.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Germany
The healthcare technology sector in Germany is rapidly evolving, driven by advancements in artificial intelligence and data-driven healthcare solutions. As one of the largest healthcare markets in Europe, Germany has a robust demand for innovative te
Similar Deals
Creathor Ventures → Acousia Therapeutics GmbH
2023
DeepTech & Climate Fonds
invested in
Clinomic
in 2025
in a Series B deal
Disclosed details
Transaction Size: $25M